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Abstract
Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive
clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen
receptor (ER)-matched invasive carcinomas of no special type (IC-NSTs). The aims of this study were to determine
whether MPCs are underpinned by a recurrent fusion gene(s) or mutations in 273 genes recurrently mutated
in breast cancer. Sixteen MPCs were subjected to microarray-based comparative genomic hybridization (aCGH)
analysis and Sequenom OncoCarta mutation analysis. Eight and five MPCs were subjected to targeted capture
and RNA sequencing, respectively. aCGH analysis confirmed our previous observations about the repertoire of
CNAs of MPCs. Sequencing analysis revealed a spectrum of mutations similar to those of luminal B IC-NSTs,
and recurrent mutations affecting mitogen-activated protein kinase family genes and NBPF10. RNA-sequencing
analysis identified 17 high-confidence fusion genes, eight of which were validated and two of which were
in-frame. No recurrent fusions were identified in an independent series of MPCs and IC-NSTs. Forced expression
of in-frame fusion genes (SLC2A1–FAF1 and BCAS4–AURKA) resulted in increased viability of breast cancer cells.
In addition, genomic disruption of CDK12 caused by out-of-frame rearrangements was found in one MPC and
in 13% of HER2-positive breast cancers, identified through a re-analysis of publicly available massively parallel
sequencing data. In vitro analyses revealed that CDK12 gene disruption results in sensitivity to PARP inhibition,
and forced expression of wild-type CDK12 in a CDK12-null cell line model resulted in relative resistance to PARP
inhibition. Our findings demonstrate that MPCs are neither defined by highly recurrent mutations in the 273
genes tested, nor underpinned by a recurrent fusion gene. Although seemingly private genetic events, some of the
fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer
therapeutic opportunities.
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great
Britain and Ireland.
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Introduction
Micropapillary carcinomas (MPCs) are a histological
special type of breast cancer accounting for up to 7%
of all invasive breast carcinomas [1]. These tumours
display a unique growth pattern featuring clusters of
tumour cells displaying inverted polarity immersed in
a spongy stroma, and often display extensive vascular
invasion [1]. Microarray-based comparative genomic
hybridization (aCGH) analysis carried out by our
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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group has revealed that pure and mixed MPCs are
remarkably similar at the genetic level [2] and harbour
a constellation of genetic aberrations that is distinct
from that of grade- and oestrogen receptor (ER)-
matched invasive carcinomas of no special type (IC-
NSTs, also known as invasive ductal carcinomas of
no special type) [2,3]. Our genomic analysis, however,
did not identify any specific genomic aberration that
may explain the distinctive morphology and clinical
behaviour of MPCs.
Some histological special types of breast cancer have
been shown to be underpinned by highly recurrent
fusion genes or somatic mutations (reviewed in refs
4 and 5). For instance, adenoid cystic carcinomas and
secretory carcinomas of the breast have been shown
to be characterized by recurrent specific chromosomal
translocations that lead to the formation of the recurrent
fusion genes MYB–NFIB [6] and ETV6–NTRK3 [7],
respectively, while lobular carcinomas are underpinned
by E-cadherin loss of function [4,8,9].
Massively parallel sequencing studies are providing
a comprehensive characterization of the repertoire of
mutations and fusion genes in different types of cancer
[10–16]. In breast cancer, RNA-sequencing studies
have identified a panoply of expressed fusion genes
[12–14,17], although the majority of these appear to
exist at very low prevalence or represent private events
(ie identified only in the index case) [12,17,18]. It is
currently believed that most of these fusion genes may
be mere passenger events [12,19]. Recently, however,
RNA sequencing has identified two classes of recurrent
gene rearrangements in IC-NSTs, involving genes
encoding microtubule-associated serine-threonine
kinase (MAST) and members of the Notch family
[17]. Furthermore, the presence of a chromosomal rear-
rangement resulting in the formation of a potentially
functionally relevant MAGI3–AKT3 chimeric protein
has been described in a subset of breast cancers [15].
Given the previous identification of pathognomonic
fusion genes and somatic mutations in histological
special types of breast cancer and the recent identi-
fication of recurrent expressed fusion genes in breast
cancer, the aims of this study were to determine (i)
if MPCs harbour recurrent mutations affecting 273
genes, either recurrently mutated in breast cancer or
DNA repair-related, or (ii) if MPCs are underpinned by
highly-recurrent expressed fusion genes. Furthermore,
we sought to determine the biological significance of
selected fusion genes identified in MPCs in vitro.
Materials and methods
Tumour samples
The study design is illustrated in Supplementary
Figure 1 and power calculations are described in
the Supplementary methods. In brief, two cohorts
of MPCs were analysed: 16 formalin-fixed, paraffin-
embedded (FFPE) MPCs (Table 1), five of which
had matched frozen material, and 14 additional FFPE
MPCs, employed as a validation cohort. In addition,
control groups of 16 IC-NSTs and 14 IC-NSTs grade-
and ER-matched to the two series of MPCs were
employed. Finally, an additional 48 grade 3 IC-NSTs
were retrieved from the authors’ institutions and sur-
veyed for the presence of specific fusion transcripts
(Supplementary methods and Supplementary Table 1).
This study was approved by the authors’ local research
ethics committees.
Immunohistochemistry
Representative sections of each case were subjected
to immunohistochemical assessment using antibodies
against epithelial membrane antigen, ER, progesterone
receptor (PR), and HER2 as previously described [2,3]
Table 1. Main cohort of 16 microdissected MPCs subjected to microarray-based comparative genomic hybridization and Sequenom
MassARRAY OncoCarta analysis. Five of the cases were subjected to RNA massively parallel sequencing due to the availability of a frozen
specimen
Sample Pure/mixed Specimen type Grade ER PR HER2 RNA-seq Mutation∗
MPC10 Pure Frozen 3 Positive Positive Negative Y None
MPC08 Pure Frozen 2 Positive Positive Negative Y None
MPC70 Pure Frozen 2 Positive Positive Negative Y None
MPC72 Pure Frozen 3 Positive Negative Negative Y None
MPC71 Pure Frozen 3 Positive Positive Positive Y None
MPC37 Mixed Frozen 3 Positive Positive Negative NP None
MPC06 Pure FFPE 2 Positive Positive Negative NP None
MPC11 Pure FFPE 2 Positive Positive Negative NP None
MPC02 Pure FFPE 2 Positive Positive Negative NP None
MPC04 Pure FFPE 3 Positive Negative Negative NP None
MPC01 Pure FFPE 2 Positive Positive Negative NP None
MPC23 Pure FFPE 3 Positive Negative Negative NP None
MPC25 Mixed FFPE 2 Positive Positive Negative NP PIK3CA H1047R
MPC45 Mixed FFPE 3 Positive Positive Positive NP None
MPC38 Mixed FFPE 3 Positive Positive Negative NP None
MPC53 Mixed FFPE 3 Negative Negative Positive NP None
ER, oestrogen receptor; FFPE, formalin-fixed, paraffin-embedded; NP, not performed; PR, progesterone receptor; RNA-seq, paired-end massively parallel mRNA
sequencing; Y, yes.
∗Mutations in the hotspot regions of 19 genes assessed by the Sequenom OncoCarta v1.0.
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and were reviewed by at least two pathologists (CM,
AS, and/or JSR-F), using previously defined scoring
systems and cut-offs [2,3,20] (Supplementary methods
and Supplementary Table 2).
Microdissection, DNA extraction, and RNA
extraction
Representative 8-µm-thick sections of the MPCs and
IC-NSTs were subjected to microdissection with a
sterile needle under a stereomicroscope (Olympus
SZ61, Tokyo, Japan) to ensure a percentage of tumour
cells greater than 90%, as previously described [3,21].
DNA extraction, quantification, and quality control
assessment were performed as previously described
[3,21] (Supplementary methods). From eight of the
16 MPCs microdissected, adjacent normal breast tissue
was successfully microdissected.
Microarray comparative genomic hybridization
(aCGH)
Sixteen MPCs and 16 grade-, ER-, and HER2-matched
IC-NSTs were subjected to aCGH analysis using a plat-
form that comprised ∼32 000 BAC clones tiled across
the genome [22]. This platform has been shown to
be as robust as, and to have comparable resolution
to high-density oligonucleotide arrays [23–25]. DNA
labelling, array hybridization, image acquisition, and
data analysis were performed as previously described
[3,22,26,27] (Supplementary methods). Data, the anal-
ysis history, script, and code are available at http://
rock.icr.ac.uk/collaborations/Mackay/Micropapillary.
Mutation screening and validation
Sixteen MPCs and 16 grade-, ER-, and HER2-matched
IC-NSTs were subjected to hotspot mutation screen-
ing of 19 known cancer genes using the OncoCarta
Panel v 1.0 (Sequenom, San Diego, CA, USA) and val-
idated using Sanger sequencing as previously described
[22,27]. For eight of these cases, sufficient DNA
from tumour and normal breast was available for tar-
geted capture massively parallel sequencing analysis
using a bait library targeting 273 genes either recur-
rently mutated in breast cancer or DNA repair-related
genes as previously described [2,28–35] (Supplemen-
tary methods and Supplementary Table 3).
Paired-end massively parallel RNA sequencing
Five pure frozen MPCs were subjected to mRNA
massively parallel sequencing, which was performed
according to the standard Illumina mRNA paired-end
library protocol (Illumina Inc, San Diego, CA, USA)
as previously described [36]. Paired-end sequencing
was performed using 2 × 54 bp cycles on the
Genome Analyser IIx (Illumina; Supplementary meth-
ods). Data were aligned to the genome and transcrip-
tome using Bowtie [37]. Mate-pairs supporting novel
chimeric transcripts were identified using ChimeraScan
version 4.0.3.0 as previously described [17,37]. High-
confidence chimeric transcripts were nominated sub-
sequent to further filtering to remove multi-mapping
reads and to exclude false-positive nominations [37].
Reverse-transcription PCR (RT-PCR), PCR,
and Sanger sequencing validation
Nominated fusion genes were validated in five index
cases by RT-PCR and Sanger sequencing as previously
described [18] (Supplementary methods). Validated in-
frame and out-of-frame fusion genes with recurrent
partners found in independent datasets [12,15–17]
were screened at the cDNA level in an independent
cohort of MPCs (n= 14), grade- and ER-matched IC-
NSTs (n = 14), and grade 3 IC-NSTs (n= 48) using
RT-PCR or quantitative real-time PCR (qRT-PCR;
Supplementary methods).
Constructs for functional analyses
The SLC2A1–FAF1 and BCAS4–AURKA fusion open
reading frames (ORFs) were PCR-amplified from the
index tumour (MPC10) and cloned into a mam-
malian expression vector pCMVentry, with a C-
terminal DDK tag (OriGene, Rockville, MD, USA).
Full-length expression constructs of FAF1 , AURKA,
and RAE1 with DDK tags were obtained from Ori-
Gene. Expression of the fusion and wild-type protein
constructs was detected with the anti-DDK monoclonal
antibody 4C5 (Origene) by western blotting of 20 µg of
whole cell protein lysate as previously described [38].
Sequences of the ORFs are available at http://rock.
icr.ac.uk/collaborations/Mackay/Micropapillary.
Cell line models
The ER-positive breast cancer cell lines, MCF7,
BT474, T47D, and ZR75.1, whose phenotypic charac-
teristics and patterns of copy number aberrations are
consistent with those of the MPCs (Supplementary
Table 4), and 12 HER2 -amplified cell lines (JIMT1,
UACC812, UACC893, VP229, SKBR3, ZR75.30,
HCC1569, HCC1954, MDA-MB-453, MDA-MB-361,
SUM225, and SUM190) were included in this study.
The sources, growth conditions, and authentica-
tion methods are described in the Supplementary
methods.
Functional assessment of in-frame fusion genes
Cloned SLC2A1-FAF1 and BCAS4-AURKA fusions,
full-length 3′ partner gene constructs or empty vec-
tors were transfected into four ER-positive breast can-
cer cell lines (MCF7, BT474, T47D, and ZR75.1)
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). Antibiotic selection was performed as pre-
viously described [38], and cell populations were
assessed every 24 h, for 9 days, using the CellTiter-
Glo cell viability assay (Promega, Madison, WI,
USA) [38], with each reading normalized to day 1 to
determine the fold change (Supplementary methods).
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Functional assessment of out-of-frame fusion genes
Short-interfering RNA (siRNA) silencing of CDK12
was performed as previously described [38,39]. Briefly,
MCF7, T47D, and SUM149 breast cancer cells were
transfected with siGENOME SMARTpools (each
containing four distinct siRNAs targeting each gene),
a non-targeting negative control siRNA (siCON), and
a positive control siRNA targeting PLK1 (siCDK12:
M-004031-03; siControl: D-001206-14; siPLK1:
M-003290-01; Fermentas, Germany). Transfection
mixes contained 50 nM siRNA in a final volume
of 100 µl, together with Lipofectamine RNAiMAX
reagent (Invitrogen). CDK12 silencing was confirmed
at the protein level by western blotting using an anti-
CDK12 antibody (ab37914; Abcam, Cambridge, MA,
USA).
Long-term survival assay
Long-term 14-day survival assays were performed
using six-well plates in triplicate as previously
described [38,39]. The sulforhodamine B (SRB)
(Sigma) assay was employed as readout as described
previously [38,39] (Supplementary methods). The
PARP inhibitor BMN673 was a kind gift from
BioMarin Pharmaceuticals (San Rafael, CA, USA),
and olaparib (AZD2281/KU0058948) was obtained
from SelleckBio (Munich, Germany).
Analysis of RAD51 foci formation
Nuclear RAD51 and phospho-γ-H2AX foci were visu-
alized and quantified as previously described [38,39]
and used as surrogate markers for induction of DNA
double-strand breaks (DSBs) and competent homol-
ogous recombination (HR) DNA repair, respectively
(Supplementary methods).
Statistical analyses
The statistical analysis methods employed are
described in the Supplementary methods.
Results
The landscape of gene copy number aberrations
and somatic mutations in MPCs
Genome-wide aCGH profiling of 16 MPCs revealed
extensive changes in the genome, ranging from 10.4%
to 54.3% of BACs showing either gains or losses
(mean: 28.5%; median: 28.9%). Consistent with the
results of our previous studies [2,3,40], the most
frequent recurrent changes included gains of 1q, 8q,
17q, and 20q, and losses of 1p 8p, 13q, 16q, and 22q
(Figure 1 and Supplementary Table 5). The majority
of MPCs (10/16 cases; 62.5%) showed high-level
gain of the whole arm of chromosome 8q, regardless
of histological grade, as previously reported [3].
Recurrent (n > 1) focal (< 2 Mb) amplifications con-
taining known genes were identified on chromosomes
1p34.3–p34.2, 8p12–p11.21, 17q11.1–q21.2, and
20q13.13–q13.2 (Supplementary Table 5).
To determine whether MPCs would be underpinned
by a pathognomonic somatic mutation, eight sam-
ples were subjected to targeted massively parallel
sequencing comprising 273 genes, and 16 samples
were subjected to Sequenom mutation profiling using
the OncoCarta panel [22,27]. We identified recurrent
mutations affecting genes of the mitogen-activated
protein kinase family (MAP3K1 in three cases,
and MAP2K6 and MAP3K4 in one case each) and
recurrent splice-site mutations of NBPF10 (n= 2)
(Table 2). A significant enrichment in genes mutated
in luminal B breast cancers was observed in the con-
stellation of mutations found in MPCs; out of the 119
genes most frequently mutated (ie ≥ 4 cases – 3.5%)
in luminal B IC-NSTs from The Cancer Genome
Atlas (TCGA) study [16], TP53 (W53*), PIK3CA
(H1047R), CSMD2 (R3608S), MAP3K1 (insertions
and deletions in three cases), ATRX (P667T), HMCN1
(A537G), MLL2 (A946E), SPEN (ESS2280A), and
ZFHX4 (A2896S) were mutated in MPC samples
(representation factor = 2.3; hypergeometric test p
value< 0.01; Table 2). Sequenom analysis confirmed
the results of the massively parallel sequencing
analysis; of the hotspot mutations included in the
OncoCarta panel, the PIK3CA H1047R mutation was
identified in the MPC reported to have this mutation
by massively parallel sequencing (MPC25). This
mutation was also validated by Sanger sequencing
(Supplementary Figure 2). In addition, MAP3K1 ,
MAP3K4 , PIK3CA, NBPF10 , CECR2 , and CSMD2 ,
which were mutated in the MPCs analysed here,
were also shown to be mutated in at least one of
the four cases of pure and mixed MPC included in
the TCGA study (http://www.cbioportal.org/public-
portal/study.do?cancer_study_id=brca_tcga_pub,
assessed on 3 December 2013). Taken together,
our results suggest that MPCs are not driven by a
pathognomonic mutation affecting any of the 273
genes included in our targeted capture massively
parallel sequencing panel, and that genes mutated in
luminal B IC-NSTs are also mutated in MPCs.
Identification of expressed fusion transcripts
in MPCs
RNA sequencing of five frozen MPCs resulted in a
total amount of sequencing per sample of 1.33–1.92
Gb per lane, median 1.37 Gb per lane (Supplementary
Table 6). Fusion transcript detection using ChimeraS-
can [37] identified 18 high-confidence chimeric tran-
scripts in four MPCs (MPC10, MPC08, MPC71, and
MPC72; Figure 1 and Table 3). In MPCs harbour-
ing expressed fusion genes, the number of nominated
high-confidence chimeras ranged from 11 in MPC10
to one in MPC72. MPC70 had no nominated high-
confidence chimeric transcripts; no differences in the
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Figure 1. Microarray-based comparative genomic hybridization frequency plots and RNA-sequencing circos plots of micropapillary
carcinomas of the breast. (A) Frequency plot of copy number gains and losses in 16 micropapillary carcinomas of the breast. The proportion
of tumours in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y-axis) for each
BAC clone according to its genomic position (x-axis). (B) Frequency plot of amplifications in 16 micropapillary carcinomas of the breast.
The proportion of tumours in which each BAC clone is amplified (green bars) is plotted (y-axis) for each BAC clone according to its genomic
position (x-axis). The red dashed line indicates the threshold for recurrent events. (C) High-confidence validated expressed fusion genes
are plotted in purple and high-confidence non-validated fusions in grey, linking the genomic locus of each partner of the fusion genes.
Genome plots, based on the 32K aCGH data, are plotted in the inner circle (green, copy number gains; red, copy number losses; black, no
copy number changes). MPC, micropapillary carcinoma of the breast.
total number of aligned reads were found between
cases that expressed fusion genes and those that did
not (data not shown). Nominated chimeric transcripts
were subsequently validated in each index case by RT-
PCR and Sanger sequencing (Figure 2), of which eight
of the 17 fusions were validated (Table 3). qRT-PCR
was used to confirm expression of in-frame fusion
genes (Supplementary Figure 3). One or both of the
partner genes involved in seven of the eight fusion
genes were amplified as defined by aCGH analysis
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Table 2. Somatic mutations identified by massively parallel sequencing in eight micropapillary carcinomas of the breast
Gene Mutation Mutation type MAF Depth Tumour sample
AGFG2 A443T Non-synonymous coding 35·70% 366 MPC02T
AKT1 E17K Non-synonymous coding 31·70% 253 MPC06T
APC R2714L Non-synonymous coding 4·80% 156 MPC25T
ATRX P667T Non-synonymous coding 9·43% 156 MPC37T
CDC25B R137W Non-synonymous coding 18·49% 799 MPC53T
CHD4 N789I Non-synonymous coding 6·90% 284 MPC06T
CSMD2 R3608S Non-synonymous coding 5·81% 149 MPC25T
CUBN N3576K Non-synonymous coding 7·46% 204 MPC37T
DCHS2 R434S Non-synonymous coding 10·42% 147 MPC37T
DOCK11 H833D Non-synonymous coding 30·80% 132 MPC08T
DST P5601Q Non-synonymous coding 7·81% 130 MPC10T
FBN1 P83S Non-synonymous coding 16·00% 273 MPC53T
FOXA1 Y259D Non-synonymous coding 23·80% 179 MPC06T
FOXA1 P248S Non-synonymous coding 10·30% 246 MPC06T
GPR98 L3724F Non-synonymous coding 23·74% 330 MPC53T
HMCN1 A537G Non-synonymous coding 13·60% 76 MPC10T
MAP1A S604* Stop gained 38·70% 47 MPC10T
MAP2K6 S35P Non-synonymous coding 18·40% 273 MPC53T
MAP3K4 G743R Non-synonymous coding 29·90% 459 MPC53T
MLL2 A946E Non-synonymous coding 6·10% 207 MPC08T
MST1L W378G Non-synonymous coding 23·28% 354 MPC25T
PIK3CA H1047R Non-synonymous coding 64·80% 111 MPC25T
RBBP8 R805L Non-synonymous coding 4·40% 216 MPC08T
NBPF10 – Splice site donor 37·50% 43 MPC02T
NBPF10 – Splice site donor 28·10% 50 MPC25T
SHROOM4 P769S Non-synonymous coding 21·05% 398 MPC53T
SRCAP V2835M Non-synonymous coding 20·59% 137 MPC37T
TP53 W53* Stop gained 55·30% 647 MPC53T
ZFHX4 A2896S Non-synonymous coding 6·20% 237 MPC08T
MAP3K1 R271fs Indel – frameshift – exon 31·58% 312 MPC02T
MAP3K1 K1037fs Indel – frameshift 40·00% 168 MPC02T
L1491LQP Indel – codon insertion 32·14% 263 MPC06T
ATN1 Q488QQ Indel – codon insertion 26·67% 88 MPC10T
SPEN ESS2280A Indel – codon change and deletion 34·62% 91 MPC11T
MAP3K1 T918fs Indel – frameshift 26·21% 183 MPC25T
MAP3K1 F884fs Indel – frameshift 37·50% 147 MPC25T
MAF, mutant allelic frequency; –, splice site.
(Figure 1 and Table 3). Of the eight validated fusions,
two were predicted to be in-frame (SLC2A1–FAF1 and
BCAS4–AURKA) and were both present in a single
tumour (ie MPC10; Figure 2 and Supplementary Figure
3). Both of these fusions were found to map to break-
points of amplification (Table 3).
RT-PCR analysis of a series of 14 independent
MPCs and 62 IC-NSTs (Supplementary Table 1 and
Supplementary Figure 4) revealed no additional case
harbouring these fusion transcripts. Of interest, how-
ever, both SLC2A1–FAF1 and BCAS4–AURKA fusion
genes were found to be present in the lymph-node
metastasis of the index case MPC10 (Supplementary
Figure 3). We next sought to determine whether one or
both partner genes of all validated chimeric transcripts
would be involved in fusion genes in other breast
cancers. Publicly available next-generation sequencing
breast cancer datasets (n= 185) [12,15–17,41–43]
were interrogated and revealed that BCAS4 is the 5′
partner gene in the validated fusion BCAS4–BCAS3
in MCF7 cells [13,17] and that FAF1 is involved
in a DNA rearrangement in an ER-negative/HER2-
negative primary breast cancer. None of the other
genes of these in-frame fusions were found to be
involved in previously reported fusion genes in breast
cancers. Of the out-of-frame validated chimeras, we
identified recurrent expressed chimeric transcripts
involving CDK12 (2.7%) and RAE1 (1%), and
DNA rearrangements involving C17ORF57 (0.5%),
NSF (0.5%), USH2A (0.5%), and LASP1 (1%)
from unselected breast cancers in external datasets
[12,15–17,41–43] (Supplementary Table 7).
Assessment of the biological relevance of selected
fusion genes identified in MPCs
Given that SLC2A1–FAF1 and BCAS4–AURKA
fusion genes were present in both the primary tumour
and lymph node metastasis of MPC10, we hypoth-
esized that, albeit restricted to a single case, these
fusion genes could constitute driver events. Therefore,
the chimeric transcript and each partner gene were
transiently expressed in four ER-positive/HER2-
negative breast cancer cell lines, including MCF7,
which is reported to recapitulate many of the pheno-
typic characteristics of MPCs [44]. Forced expression
of SLC2A1–FAF1 caused a significant increase in
cell proliferation compared with the empty vector
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Table 3. Identification of expressed chimeric transcripts in five micropapillary breast carcinomas
Sample ID Gene 5′ Gene 3′ Mapping 5′ Mapping 3′
Total
reads
Spanning
reads
In
frame Validated
Copy
number 5′
Copy
number 3′
MPC10 ELMO2 RAE1 chr20:45014762 chr20:55943760 25 14 No Y Gain Amp
MPC10 BCAS4 AURKA chr20:49411466 chr20:54944444 24 1 Yes Y Gain Amp
MPC10 SLC2A1 FAF1 chr1:43424304 chr1:50906934 12 5 Yes Y Amp Gain
MPC10 TSEN54 UNC84A chr17:73512608 chr7:934970 7 0 No N Gain Gain
MPC10 CD46 USH2A chr1:207925401 chr1:215796235 6 1 No Y Amp Gain
MPC71 LASP1 CDK12 chr17:37026111 chr17:37646809 5 4 No Y Amp Amp
MPC10 DENND1C SURF1 chr19:6470305 chr9:136218665 4 0 Yes N No change No change
MPC10 UBE2V1 SULF2 chr20:48713208 chr20:46286150 4 1 No Y Amp Amp
MPC08 BC018860 CDK5RAP3 chr1:566461 chr17:46052524 3 1 No N No change No change
MPC10 LRRC6 HPRG1 chr8:133584447 chr8:133572744 3 0 No N Amp Amp
MPC08 PDLIM5 TCEB1 chr4:95373037 chr8:74858633 3 3 No N No change Amp
MPC08 TSPAN14 DYDC2 chr10:82214037 chr10:82126443 3 1 No N Amp No change
MPC10 IFI44L IFI44 chr1:79086087 chr1:79115476 2 0 No N Loss Loss
MPC10 MRPL21 BX640963 chr11:68660870 chr2:69686413 2 0 No N No change No change
MPC10 SYNGAP1 RALY chr6:33387846 chr20:32664833 2 0 No N Gain Gain
MPC72 MUC1 C1orf86 chr1:155161501 chr1:2115916 2 0 No N Gain Loss
MPC71 CYB5B CALB2 chr16:69458497 chr16:71416621 2 2 No Y No change No change
MPC71 NSF C17orf57 chr17:44668037 chr17:45438743 2 2 No Y Amp No change
5′ , 5′ partner gene; 3′ , 3′ partner gene; total reads, total number of reads supporting the nominated fusion; spanning reads, number of reads spanning the fusion
junction.
Copy number derived from smoothed cbs ratios of aCGH data; loss, copy number loss; no change, no copy number change; gain, copy number gain, amp, amplification.
Figure 2. Structure of validated high-confidence fusion genes in micropapillary carcinomas. Sanger sequencing validation of functionally
assessed fusion genes in the index cases of micropapillary carcinomas (MPCs) (BCAS4–AURKA and SLC2A1–FAF1 in MPC10 and
LASP1-CDK12 in MPC71). (A) Haematoxylin and eosin (H&E) and epithelial membrane antigen (EMA) staining of representative areas of
the MPCs harbouring the BCAS4–AURKA, SLC2A1–FAF1, and LASP1–CDK12 fusion genes (10× original magnification). (B) Schematic
representation of nominated fusion transcripts. Fusion junctions with respective exon numbers are shown, while paler colours indicate 3′
and 5′ UTRs. (C) cDNA level sequence chromatograms spanning the junction (dotted line) of the fusion transcript.
control (as measured by fold change in cell viability
on day 9 in each cell line; Figure 3A) in two out of
four cancer cell lines (ie MCF7 and BT474, p < 0.05,
one-way ANOVA). Forced expression of full-length
FAF1 had a similar effect only in MCF7 and BT474
cells (Figure 3A). BCAS4–AURKA forced expression
caused a significant increase in cell proliferation,
compared with the empty vector, in one cell line
(MCF7, p < 0.05, one-way ANOVA). Again, forced
expression of the 3′ partner, AURKA, recapitulated
these results only in MCF7 (Figure 3B). These data
suggest that some private, or low-frequency, fusion
genes may provide a selective advantage, which may
also be dependent on the phenotype and genetic
make-up of the cell harbouring them (Figure 3C).
Out-of-frame fusion genes may provide a selective
advantage to cancer cells harbouring them by disrupt-
ing the expression of genes with tumour suppressor
roles [45,46]. Given that CDK12 maps to the smallest
region of amplification of the HER2 amplicon,
and recurrent fusions were identified in 13% (6/47)
HER2 -amplified tumours (Supplementary Table 7), we
hypothesized that disruptions involving CDK12 were
due to a copy number breakpoint within the amplicon.
By mining aCGH and matched gene expression data
from HER2 -amplified cells lines [47], we identified
7/14 HER2 -amplified cells where a breakpoint within
the HER2 amplicon mapped to CDK12 (Supplemen-
tary Table 4). A significant reduction in CDK12 mRNA
expression was observed in these cell lines relative to
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Figure 3. Functional assessment of in-frame expressed fusion genes. To determine the biological significance of the in-frame fusion genes
identified in MPCs, forced expression of each fusion gene (SLC2A1–FAF1, A and BCAS4–AURKA, B), the 3′ partner gene, and an empty
vector was performed in a panel of breast cancer cell lines. The fold change in cell population (y-axis) is plotted against growth time (days,
x-axis). Red, solid black, and dashed black lines denote growth curves following transfection with fusion gene constructs (ie SLC2A1–FAF1
or BCAS4–AURKA), full-length 3′ partner genes (ie FAF1 or AURKA), and empty vector (pCMV), respectively. Western blotting using
anti-DDK antibody was employed to confirm exogenous expression of cDNA constructs following transfection in MCF7 cells (A and B).
In A and B, statistically significant differences are highlighted with an asterisk. (C) A matrix illustrating the pathological phenotype and
aberrations affecting endogenous fusion gene partners in the cell lines employed, where dark blue squares represent positivity in a marker,
light blue squares represent negativity in a marker, green squares denote amplification of a gene, and red denotes rearrangement of a gene.
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HER2 -amplified breast cancer cell lines that did not
harbour a breakpoint involving CDK12 (Figure 4A;
p = 0.0360, t-test). Assessment of CDK12 protein
expression in this panel of cells revealed a significantly
lower level of protein expression (p = 0.0438, t-test;
Figure 4B), with MDA-MB-453 showing no detectable
levels of CDK12 protein expression. CDK12 has
recently been reported to be involved in the mainte-
nance of genomic stability through regulation of genes
involved in the DNA damage response pathway includ-
ing BRCA1 , ATR, FANCI , and FANCD2 , and cells
devoid of CDK12 have been reported to be sensitive
to DNA-damaging agents [48]. To determine whether
HER2 -amplified cells with breakpoints in CDK12
were sensitive to PARP inhibitors, we investigated the
sensitivity of HER2 -amplified and ER-positive breast
cancer cell lines to BMN673 (Figure 4C) and olaparib
(Supplementary Figure 5). Although there was no
difference in sensitivity comparing the SF50 to cell
lines with and without CDK12 disruption (p = 0.207,
BMN673 and p = 0.375, olaparib, t-test), MDA-MB-
453 cells that are null for CDK12 expression were
sensitive to both BMN673 and olaparib. Silencing of
CDK12 mediated by siRNA in ER-positive cell lines
MCF7 and T47D resulted in increased sensitivity to the
PARP inhibitor BMN673 (Figure 4D). Furthermore, the
ability to elicit RAD51 foci formation upon treatment
with ionizing radiation or the PARP inhibitor BMN673
was diminished upon CDK12 silencing (Figure 4E and
Supplementary Figure 6). Reconstitution of wild-type
CDK12 in MDA-MB-453 CDK12 null cells rendered
cells more resistant to both BMN673 (Figure 4F) and
olaparib (Supplementary Figure 5).
Taken together, our results demonstrate that MPCs
do not harbour highly-recurrent fusion genes; how-
ever, some of the in-frame private fusion genes iden-
tified in this study have a biological impact that is
likely to be context-dependent and may be part of a
convergent phenotype. Loss of CDK12 due to break-
points in the HER2 amplicon results in sensitivity to
PARP inhibitors, suggesting that some out-of-frame
fusion genes may represent bona fide loss-of-function
genomic events, and potentially targetable somatic
genetic aberrations.
Discussion
In this analysis of breast MPCs, not only have we con-
firmed the patterns of gene copy number aberrations
previously reported by our group [2,3] in this spe-
cial type of breast cancer, but we have also provided
direct evidence to rule out two potential mechanisms
that result in breast cancers displaying a micropapil-
lary phenotype: (i) pathognomonic mutations in genes
recurrently mutated in breast cancer and DNA repair-
related genes and (ii) highly-recurrent expressed fusion
genes. In fact, our analysis revealed recurrent mutations
affecting MAPK genes. In addition, mutations affect-
ing genes often mutated in luminal B IC-NSTs have
also been found in individual MPC samples (Table 2).
This finding confirms our previous observation that
MPCs have a constellation of genetic aberrations sim-
ilar to those of luminal B breast cancers [2,3] and
rules out the possibility that the MPC phenotype is
driven by pathognomonic mutations affecting any of
the 273 recurrently mutated breast cancer and DNA
repair-related genes included in the targeted capture
sequencing platform employed (Supplementary Table
3) and in the Sequenom OncoCarta panel. Further-
more, paired-end massively parallel RNA-sequencing
revealed that although fusion genes are present in a
proportion of MPCs, these constitute private genetic
events (ie restricted to the index case) and often map
to regions of amplification.
Two of the in-frame expressed fusion genes
identified in this study, SLC2A1–FAF1 and
BCAS4–AURKA, were present both in the primary
tumour MPC10 and in the corresponding synchronous
lymph-node metastasis (MPC10LND). Although this
observation may merely indicate that these fusion
genes were present in the modal clonal population
of MPCs, it is possible that their maintenance in the
metastatic deposit was due to a selective advantage
conferred by the expression of the chimeric fusion
genes. To test whether these fusion genes would confer
a growth/survival advantage, we forced the expression
of the chimeric fusion transcripts and each 3′ partner
in four ER-positive, HER2-negative breast cancer cell
lines. Similar to driver fusion genes identified by RNA
sequencing analysis of breast cancer [17], ectopic
overexpression of these in-frame fusion genes resulted
in increased proliferation of multiple breast cancer cell
lines, which was similar to the effect of the ectopic
expression of the 3′ partner genes. It should be noted,
however, that different ER-positive breast cancer cell
lines responded differently to the forced expression of
the fusion genes SLC2A1–FAF1 and BCAS4–AURKA,
and their wild-type fusion gene partners (Figure 3).
The SLC2A1–FAF1 fusion involves a promoter swap
of the major glucose transporter SLC2A1 exon 1
fused to exons 13–16 of FAF1. FAF1 (FAS associate
factor 1) encodes for a protein that binds to FAS
antigen and initiates apoptosis; its down-regulation
may contribute to tumourigenesis, through the regu-
lation of apoptosis and NFκB activity, as well as in
ubiquitination and proteasomal degradation [49]. The
fusion gene found in MPC10 contains the ubiquitin
association and ubiquitin-like regulatory X domain
[49]. The BCAS4–AURKA fusion gene results in the
preservation of the AURKA kinase domain being
driven by the promoter sequences of BCAS4 . The
loci of BCAS4 and AURKA (ie 20q13) are amplified
in MPC10 and in MCF7 cells. AURKA encodes for
Aurora Kinase A, a serine-threonine kinase mainly
involved in centrosome duplication, mitotic entry,
and spindle assembly [50]. Although AURKA gene
amplification is a common genetic aberration in breast
cancer [16], its role as a therapeutic target for breast
cancers harbouring amplification of this locus remains
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 553–565
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
562 R Natrajan et al
Figure 4. Disruption of CDK12 leads to PARP inhibitor sensitivity. (A) mRNA expression of CDK12 in HER2-amplified cell lines with a
breakpoint spanning the CDK12 locus shows significantly lower levels of CDK12 mRNA compared with cells without a breakpoint spanning
CDK12. (B) Western blot analysis of endogenous CDK12 in a panel of HER2-amplified cell lines relative to β-actin loading control.
BT474 (blue) was employed as a loading control for normalization of the results of the western blot. Note that MDA-MB-453 shows no
CDK12 expression (red), and relative quantification of CDK12 protein expression relative to β-actin, showing a significantly lower level of
expression in cell lines with a breakpoint spanning CDK12 than those without (p = 0.0438, t-test). (C) Log10 SF50 of HER2-amplified cell
lines to the PARP inhibitor BMN673. SUM149 in blue as a positive control, given that this cell line harbours a BRCA1 mutation. (D) CDK12
silencing results in increased sensitivity to BMN673 in T47D and MCF7 ER-positive breast cancer cells. The BRCA1 mutant SUM149 cells
displayed no increase in sensitivity upon CDK12 silencing, suggesting that the PARP inhibitor sensitivity caused by silencing of this gene
results from impaired homologous recombination DNA repair. Western blot showing expression of CDK12 in T47D, MCF7, and SUM149
cells relative to β-actin loading control. (E) Percentage of cells with RAD51 positive foci normalized to phospho-γ-H2AX foci formation
without treatment (Ctrl), 6 h after 10 Gy (IR) of irradiation, and with 1 mM BMN673 for 24 h (PARPi), with (red) and without (grey) CDK12
silencing. (F) Reconstitution of full-length CDK12 (blue) and empty vector (p.CMV) (black) in MDA-MB-453 cells treated with BMN673.
Western blot showing expression of CDK12 in MDA-MB-453 cells transfected with full-length CDK12.
to be fully established. Taken together, these findings
suggest that some private fusion genes may provide
a growth/survival advantage to cancer cells and that
this advantage is context-dependent and may be the
product of epistatic interactions.
Some of the partner genes of the validated chimeric
transcripts found in the present study were shown
to be involved in other somatic rearrangements in
breast cancers. CDK12 , LASP1 , RAE1 , C17orf57 ,
NSF , and USH2A were partners of out-of-frame, but
not in-frame, fusion genes here and in other mas-
sively parallel sequencing analyses of breast cancers
[12,15–17,41–43] (Supplementary Table 7). It is
plausible that these out-of-frame rearrangements result
in loss of function of one or both partners involved.
Re-analysis of publicly available data revealed that
CDK12 may constitute a tumour suppresser gene as
it is recurrently targeted not only by DNA rearrange-
ments in breast (2.6% of unselected breast cancers;
13% of HER2 -amplified breast cancers) and 1/17
(5%) HER2 -amplified gastric cancers [51], but also by
nonsense mutations in 1.5% of triple-negative breast
cancers [43]. Consistent with this notion, CDK12 has
been shown to be related to DNA repair, given that
it plays a role in the regulation of transcription. In
addition, depletion of CDK12 results in decreased
expression of predominantly long genes with high
numbers of exons, in particular DNA damage response
genes, including BRCA1 , ATR, FANCI , and FANCD2 .
CDK12-deficient cells display spontaneous DNA
damage and are sensitive to a variety of DNA-
damaging agents [48]. Here we have demonstrated
that RNA-interference-mediated silencing of CDK12
in ER-positive cell lines resulted in increased sensitiv-
ity to PARP inhibition and a reduction in the ability to
form RAD51 foci in the nucleus upon DNA damage
through irradiation or PARP inhibition. Furthermore,
MDA-MB-453 cells, which lack CDK12, displayed
sensitivity to PARP inhibition, which was rescued upon
re-expression of full-length CDK12. These observa-
tions suggest that the subset of HER2 -amplified breast
cancers harbouring a disruption of CDK12 through
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somatic rearrangements may benefit from treatment
with PARP inhibitors, and provide a molecular ratio-
nale for the testing of these agents in HER2-positive
disease.
This study has several limitations. First, the small
number of cases subjected to mRNA sequencing could
have resulted in a type II/β-error in the search of a
highly-recurrent pathognomonic event; however, by
the sequencing of five samples we should have been
able to identify a recurrent event (ie with a prevalence
similar to FOXL2 mutations in granulosa cell tumours
of the ovary [52]) with 97% statistical power. Second,
although cell lines constitutively harbouring the
in-frame fusion genes identified in primary MPCs
were not available, our results demonstrate that forced
expression of SLC2A1–FAF1 and BCAS4–AURKA
results in increased growth/survival in multiple breast
cancer cells.
In conclusion, our findings demonstrate that the
MPC phenotype in breast cancers is neither driven
by pathognomonic mutations affecting the 273 recur-
rently mutated breast cancer and DNA repair-related
genes tested in this study, nor is it underpinned by a
highly-recurrent pathognomonic expressed fusion gene.
Although the fusion genes identified in this study were
private events, we have provided circumstantial evi-
dence to suggest that at least some private in-frame
expressed fusion genes may also be driver events and
impact on cancer cell proliferation. Finally, some of the
out-of-frame CDK12 rearrangements in HER2-positive
breast cancers were shown to lead to a potential loss
of function and provide a rationale for treating a subset
of HER2 -amplified patients with PARP inhibitors.
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